# Sylvain Ladoire

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sylvain-ladoire/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,779 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 56 |
| i10-index | 143 |
| Last Known Institution | Inserm |
| OpenAlex ID | https://openalex.org/A5059810021 |
| ORCID iD | https://orcid.org/0000-0002-0331-9194 |
| Works | 421 |

## Researcher papers

- [Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy](https://scholariq.org/papers/cancer-cell-autonomous-contribution-of-type-i-interferon-signaling-to-the/)
- [Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-alone-or-combined-with-chemotherapy-versus-chemotherapy-as-first/)
- [Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/switch-to-fulvestrant-and-palbociclib-versus-no-switch-in-advanced-breast-cancer/)
- [EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†](https://scholariq.org/papers/eau-esmo-consensus-statements-on-the-management-of-advanced-and-variant-bladder/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Researcher university

- [Inserm](https://scholariq.org/institutions/inserm/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.